Jesse G. Dixon

1.3k total citations
22 papers, 502 citations indexed

About

Jesse G. Dixon is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jesse G. Dixon has authored 22 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jesse G. Dixon's work include Colorectal Cancer Treatments and Studies (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Genetic factors in colorectal cancer (6 papers). Jesse G. Dixon is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Genetic factors in colorectal cancer (6 papers). Jesse G. Dixon collaborates with scholars based in United States, France and United Kingdom. Jesse G. Dixon's co-authors include Qian Shi, Christopher R. Flowers, Gilles Salles, Hervé Tilly, David Cunningham, Jocelyne Flament, Norbert Schmitz, Marita Ziepert, Corinne Haïoun and Hervé Ghesquières and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jesse G. Dixon

17 papers receiving 497 citations

Peers

Countries citing papers authored by Jesse G. Dixon

Since Specialization

Citations

This map shows the geographic impact of Jesse G. Dixon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesse G. Dixon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesse G. Dixon more than expected).

Fields of papers citing papers by Jesse G. Dixon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesse G. Dixon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesse G. Dixon. The network helps show where Jesse G. Dixon may publish in the future.

Co-authorship network of co-authors of Jesse G. Dixon

This figure shows the co-authorship network connecting the top 25 collaborators of Jesse G. Dixon. A scholar is included among the top collaborators of Jesse G. Dixon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesse G. Dixon. Jesse G. Dixon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma 2025 ·Neuro-Oncology ·William G. Breen, Jesse G. Dixon, S. Keith Anderson, Jann N. Sarkaria, Paul D. Brown, Elizabeth Yan, Sani H. Kizilbash, Evanthia Galanis, Daniel M. Anderson, David Tran, Miroslaw Mazurczak, Derek R. Johnson, Francois J. Geoffroy, (unknown), Nadia N. Laack	0
2	Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP). 2025 ·Journal of Clinical Oncology ·Qian Shi, George J. Chang, Levi Pederson, Elliot A. Asare, Zhaohui Jin, Romain Cohen, Jeffrey A. Meyerhardt, Thierry André, Jeanne Tie, Jesse G. Dixon, Bryan E. Palis, Karla V. Ballman, Greg Yothers, (unknown), Steven R. Alberts, Chanjuan Shi, M. Kay Washington, Julien Taı̈eb, (unknown), Richard M. Goldberg	0
3	Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur) 2024 ·BMC Cancer ·Kathryn Hitchcock, Eric D. Miller, Qian Shi, Jesse G. Dixon, Sepideh Gholami, Sarah B. White, Christina Wu, (unknown), Manju George, Kyung‐Wook Jee, (unknown), Rona Yaeger, Ardaman Shergill, Theodore S. Hong, Thomas J. George, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Paul B. Romesser	1
4	Alliance A022101: A pragmatic, randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: Evaluating Radiation, Ablation, and Surgery (ERASur). 2023 ·Journal of Clinical Oncology ·Kathryn Hitchcock, Paul B. Romesser, Qian Shi, Jesse G. Dixon, Sepideh Gholami, Sarah B. White, Christina Wu, (unknown), Kyung‐Wook Jee, Chadwick Wright, Rona Yaeger, Ardaman Shergill, Theodore S. Hong, Thomas J. George, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Eric D. Miller	0
5	End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma 2022 ·British Journal of Haematology ·Jesse G. Dixon, Natalie Dimier, Tina Nielsen, (unknown), Robert Marcus, Franck Morschhauser, Andrew M. Evens, Massimo Federico, Kristie A. Blum, Qian Shi	3
6	Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Jesse G. Dixon, (unknown), Dai Chihara, Tina Nielsen, Natalie Dimier, (unknown), Anna Wall, Gilles Salles, Franck Morschhauser, Robert Marcus, Michael Herold, Eva Kimby, Kristie A. Blum, Michele Ghielmini, Qian Shi, Christopher R. Flowers	0
7	Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis. 2022 ·Journal of Clinical Oncology ·Zhaohui Jin, Jesse G. Dixon, Joleen M. Hubbard, Cathy Eng, Christopher H. Lieu, Jean‐Yves Douillard, Richard Adams, Tim Maughan, Eric Van Cutsem, Alan P. Venook, Heinz‐Josef Lenz, Volker Heinemann, Sebastian Stintzing, Richard Kaplan, Carsten Bokemeyer, Benoist Chibaudel, John Zalcberg, Takayuki Yoshino, Aimery de Gramont, Qian Shi	1
8	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials 2022 ·Blood ·Carla Casulo, Jesse G. Dixon, Jennifer Le‐Rademacher, Eva Hoster, Howard S. Höchster, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Catherine Sebban, Emmanuel Gyan, Kenneth A. Foon, Tina Nielsen, Umberto Vitolo, Gilles Salles, Qian Shi, Christopher R. Flowers	85
9	Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102). 2022 ·Journal of Clinical Oncology ·Jann N. Sarkaria, Karla V. Ballman, Sani H. Kizilbash, Erik P. Sulman, Caterina Giannini, Sandeep H. Mashru, David Piccioni, Bret Edward Buckley Friday, Jesse G. Dixon, Brian Kabat, Nadia N. Laack, Leland Hu, Priya Kumthekar, Benjamin M. Ellingson, S. Keith Anderson, Evanthia Galanis	11
10	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials 2021 ·Blood Advances ·Carla Casulo, Jesse G. Dixon, Fang‐Shu Ou, Eva Hoster, B. A. Peterson, Howard S. Höchster, Pauline Brice, Marco Ladetto, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Tina Nielsen, Franck Morschhauser, Mathias Rummel, Anton Hagenbeek, Umberto Vitolo, Gilles Salles, Qian Shi, Christopher R. Flowers	3
11	Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases 2020 ·Cancer Medicine ·Kurt A. Jaeckle, Jesse G. Dixon, (unknown), Alvaro Moreno‐Aspitia, Gerardo Colón‐Otero, (unknown), Tejal Patel, (unknown), Edith A. Perez	21
12	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database. 2020 ·Journal of Clinical Oncology ·Zhaohui Jin, Jesse G. Dixon, Hiral D. Parekh, Steven R. Alberts, Greg Yothers, Carmen J. Allegra, Rachel Kerr, Daniel G. Haller, Aimery de Gramont, Takayuki Yoshino, Eric Van Cutsem, Chris Twelves, Julien Taı̈eb, Leonard B. Saltz, Jean‐François Seitz, Thierry André, Amit Mahipal, Richard M. Goldberg, Qian Shi, Thomas J. George	0
13	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI 2020 ·Blood ·Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, Anna Wall, David Cunningham, Viola Poeschel, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Marita Ziepert, Jocelyne Flament, Christopher R. Flowers, Qian Shi, Norbert Schmitz	199
14	Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) 2019 ·Journal of Neuro-Oncology ·Kurt A. Jaeckle, (unknown), Erin Twohy, Jesse G. Dixon, Caterina Giannini, Robert B. Jenkins, Merrill J. Egorin, Jann N. Sarkaria, Paul D. Brown, Patrick J. Flynn, John F. Schwerkoske, Jan C. Buckner, Evanthia Galanis	8
15	A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872 2019 ·Cancer ·Evanthia Galanis, S. Keith Anderson, Erin Twohy, Xiomara W. Carrero, Jesse G. Dixon, David Tran, Suriya Jeyapalan, Daniel M. Anderson, Timothy J. Kaufmann, Ryan W. Feathers, Caterina Giannini, Jan C. Buckner, Panos Z. Anastasiadis, David Schiff	54
16	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL). 2019 ·Journal of Clinical Oncology ·Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, Anna Wall, David Cunningham, Viola Poeschel, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Marita Ziepert, Jocelyne Flament, Christopher R. Flowers, Qian Shi, (unknown)	2
17	Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database. 2019 ·Journal of Clinical Oncology ·Qian Shi, Aimery de Gramont, Jesse G. Dixon, Jun Yin, Eric Van Cutsem, Julien Taı̈eb, Steven R. Alberts, Norman Wolmark, Hans‐Joachim Schmoll, Leonard B. Saltz, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Takayuki Yoshino, Greg Yothers, Axel Grothey, Thierry André, Mohamed E. Salem, (unknown)	2
18	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL) 2018 ·Journal of Clinical Oncology ·Qian Shi, Norbert Schmitz, Fang‐Shu Ou, Jesse G. Dixon, David Cunningham, Michael Pfreundschuh, John F. Seymour, Ulrich Jaeger, Thomas M. Habermann, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Christopher R. Flowers	47
19	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database. 2017 ·Journal of Clinical Oncology ·Fang‐Shu Ou, Joleen M. Hubbard, Pashtoon Murtaza Kasi, Jesse G. Dixon, Eric Van Cutsem, Leonard B. Saltz, Hans‐Joachim Schmoll, Cornelis J.A. Punt, Richard M. Goldberg, Paulo M. Hoff, Jean‐Yves Douillard, J. Randolph Hecht, Herbert I. Hurwitz, Carsten Bokemeyer, Charles S. Fuchs, Eduardo Díaz‐Rubio, Daniel J. Sargent, Aimery de Gramont, Qian Shi, Axel Grothey, (unknown)	5
20	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer 2016 ·Clinical Colorectal Cancer ·Ben Y. Zhang, Jeremy Jones, (unknown), Joleen M. Hubbard, Benjamin R. Kipp, Daniel J. Sargent, Jesse G. Dixon, Axel Grothey	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact